Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-TATE-RGD PET/CT for SSTR2 and αvβ3 Positive Tumors
NCT06632860Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium Ga 68-NOTA-3PTATE-RGD in neuroendocrine tumors (NETs), thyroid cancer and meningioma, sponsored by Peking Union Medical College Hospital. Primary endpoint: Tumor detection rate at 6 months. Started Aug 2024; status: recruiting.
02
Drugs
gallium Ga 68-NOTA-3PTATE-RGD
03
Conditions
neuroendocrine tumors (NETs)thyroid cancermeningioma
Beyond the preview
Go deeper on NCT06632860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632860.